Biodexa Pharmaceuticals Plc (BDRX) Form 424B3 — Sep 11, 2026
Biodexa Pharmaceuticals filed Prospectus Supplement No. 3 to its F-1 resale prospectus, covering 94,300 ordinary shares (1,886 ADSs) held by selling shareholders, and incorporating its Form 6-K interim results for the six months ended June 30, 2026. The ADSs closed at $0.6676 on Nasdaq the prior day. For 1H26 Biodexa reported nil revenue, a £1.84 million loss (1H25: £3.81 million loss), and R&D costs up 75% to £2.92 million, driven by the Serenta Phase 3 trial and the newly in-licensed MTX240 program.
Key figures
- Eps
- £(0.000005) basic and diluted loss per share
- Revenue
- £Nil
- Net Income
- £1.84 million loss (1H25: £3.81 million loss)
- Total Debt
- £0 (borrowings nil at June 30, 2026)
- Total Assets
- £12.72 million
- Cash Position
- £3.23 million at June 30, 2026 (vs £8.53 million at December 31, 2025)
- Nci grant
- US$3.0 million
- Eloc undrawn
- US$26.08 million
- Eloc capacity
- US$35 million
- Rd costs 1h25
- £1.67 million
- Rd costs 1h26
- £2.92 million (+75% YoY)
- Serenta planned
- 168
- Admin costs 1h26
- £1.74 million (-27% YoY)
- Gist market size
- US$1.3 billion
- Serenta enrolled
- 92
- Mtx240 upfront fee
- US$500,000
- Accumulated deficit
- £157.60 million
- Ads price july raise
- US$2.85 per ADS
- Nmibc trial enrolled
- 166
- Gross raise july 2026
- US$3.5 million
- Resale shares covered
- 94,300 ordinary shares (1,886 ADSs)
- Cprit grant offset percent
- 66
- Operating cash outflow 1h26
- £4.61 million
- Ordinary shares outstanding
- 373056808922
- Ads closing price sep 10 2026
- 0.6676
- Mtx240 development milestones
- US$0.5 million
AI analysis
Red flags6 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.